SCN3A: Sodium channel protein type 3 subunit alpha
Pore-forming subunit of Nav1.3, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on SCN3A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Elpetrigine | Phase 2 | — | Small molecule | BlockerSodium channel protein type III alpha subunit blocker | 0 |
- Familial focal epilepsy with variable foci0.77
- Developmental and epileptic encephalopathy, 620.76
- Epilepsy0.75
- Focal epilepsy0.73
- Seizure0.71
- Pain0.61
- Bipolar disorder0.60
- Major depressive disorder0.60
- Atrial fibrillation0.59
- Pruritus0.59
- Migraine disorder0.59
- Cardiac arrhythmia0.58
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5163, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9NY46, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets